



Viral Hepatitis Prevention Board (VHPB)



Universiteit
Antwerpen



VHPB

Almost **3 decades** active in the control
and prevention of viral hepatitis in
Europe



VHPB mission

Mission statement

The objective of VHPB is to contribute to the **control** and **prevention** of **viral hepatitis**:

- by drawing the attention to this important **public health** problem
- by issuing prevention and control guidance and catalyse the development of recommendations.
- by encouraging actions **to improve control, prevention and elimination**.

All activities are in line with **viral hepatitis elimination goals** defined by **WHO** Global strategy

Focus audiences are, in first instance, opinion leaders, policymakers, public health and health care professionals



1. Based on the available scientific evidence can treatment discontinuation for hepatitis B be considered

- If yes: when and how?

- If No: what is still needed to take an evidence based discission

2. Treatment of Hepatitis B, will it be an influencing factor to reach the elimination goals set for hepatitis B should the targets be adapted (80% of diagnosed cases) when discontinuation of treatment will be considered

Activities: Two meetings a year

- 1. Technical meeting:** discuss, review and issue guidelines or recommendations for critical issues in viral hepatitis
- 2. Country meeting:**
 - Understand strategies and programs to control viral hepatitis in the country
 - Create awareness in the country for hepatitis as a public health problem
 - Create a platform where people of the country involved in viral hepatitis can discuss and can start future initiatives
 - Verify the WHO elimination targets and monitor the progress
 - Initiate or accelerate the development of National viral hepatitis plan
 - Draft guidelines to support countries based on lessons learned from other countries

VHPB advisors

Intern. organisation



Antons Mozalevskis
WHO-Euro



Erika Duffell
ECDC



Marko Korenjak
ELPA



John Ward
Global task force



Maria Buti
EASL



Paige Armstrong
CDC

Public Health



David Goldberg
Scotland



Mira Kojouharova
Bulgaria



Silvia Bino
Albania



Sema Mandal
UK

VHPB advisors

Academic/University



Paolo Bonanni
Italy



Vladimir Chulanov
Russia



Angela Dominguez
Spain



Karine Lacombe
France



Helène Norder
Sweden



Vana Papaevangelou
Greece



Mojca Maticic
Slovenia



Rui Tato Morinho
Portugal



Daniel Shouval
Israel



Pierre Van Damme
Belgium



Thomas Van Wolleghem
Belgium/The Netherlands



VHPB TECHNICAL MEETING

+++Online+++

Long term hepatitis B vaccination and treatment

Meeting Agenda

29-30 March 2022

16h00 - 19h30 CEST



Meeting Objectives

- PART I – Vaccination
 - Long-term protection of hepatitis B vaccination
 - Provide information and data from recent and/or ongoing follow-up studies
 - Long-term impact of hepatitis B vaccination strategies including success stories
 - Discuss impact of growing vaccine hesitancy on long-term vaccination coverage
 - Discuss long term hepatitis B vaccination in relation to the WHO elimination goals
- PART II – Treatment
 - Discuss long-term outcomes of (new) hepatitis B treatment
 - Discuss treatment discontinuation

Meeting practical

- This is a very interactive meeting, questions and comments are welcome
- To facilitate the discussion
 - If you have question “raise your hand”
 - Switch on your camera →
 - Chair will allow you to intervene
 - Unmute
 - Introduce yourself shortly

